VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Shares in Aurinia Pharmaceuticals Inc $AUPH

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 113,568 shares of the biotechnology company’s stock, valued at approximately $1,927,000.

A number of other large investors also recently bought and sold shares of the stock. California State Teachers Retirement System boosted its holdings in shares of Aurinia Pharmaceuticals by 2,033.2% in the 2nd quarter. California State Teachers Retirement System now owns 2,264,799 shares of the biotechnology company’s stock valued at $38,434,000 after purchasing an additional 2,158,630 shares during the last quarter. SFG Wealth Management LLC. acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $187,000. Nykredit A S acquired a new stake in shares of Aurinia Pharmaceuticals during the 2nd quarter worth $35,000. Navellier & Associates Inc. raised its position in shares of Aurinia Pharmaceuticals by 123.7% in the 2nd quarter. Navellier & Associates Inc. now owns 257,142 shares of the biotechnology company’s stock worth $4,364,000 after buying an additional 142,206 shares during the period. Finally, Centaurus Financial Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter worth $1,113,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AUPH. Royal Bank Of Canada boosted their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research report on Friday, August 7th. Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Zacks Research cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Aurinia Pharmaceuticals Stock Down 0.1%

Shares of Aurinia Pharmaceuticals stock opened at $16.10 on Friday. The company has a fifty day moving average price of $15.81 and a 200 day moving average price of $15.61. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. Aurinia Pharmaceuticals Inc has a twelve month low of $10.34 and a twelve month high of $19.25. The stock has a market cap of $2.14 billion, a price-to-earnings ratio of 7.03 and a beta of 1.40.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current fiscal year.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.